|Mr. Vincent J. Milano||Pres, CEO & Director||952.08k||N/A||1964|
|Mr. John J. Kirby||Sr. VP & CFO||459.51k||N/A||1972|
|Mr. Bryant David Lim||Sr. VP, Gen. Counsel & Corp. Sec.||524.64k||N/A||1971|
|Mr. Robert Clayton Fletcher||Sr. VP of Bus. Devel. & Strategic Planning||591.08k||N/A||1963|
|Ms. Jill Conwell||Sr. VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.
Idera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 4.